Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement
Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing
Illumina and Oxford Nanopore Technologies announced a strategic alliance including a commercialization agreement and equity investment. Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products developed by Oxford Nanopore for DNA sequencing into the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales.
Oxford Nanopore’s new generation sequencing system uses protein nanopores coupled with a processive enzyme. This system is designed for direct electrical identification of DNA bases at the single-molecule level, without the need for fluorescent labels. Currently in development, this technology has the potential to provide substantial advantages over current sequencing approaches, not only in speed and cost but also in simplicity and versatility of overall workflow. The removal of the traditional fluorescent labeling step and reduced burden of sample preparation are highly desirable in future generations of sequencing technology.
As part of the agreement, Illumina made an equity investment of $18.0 million (£11.8 million), which will be used to accelerate the development of BASETM Technology. Illumina has also agreed to make an additional equity investment upon the achievement of a specific technical milestone.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Imaging biomarker distinguishes prostate cancer tumor grade - Enhanced imaging tool has potential to detect, grade, stage and guide treatment options
BÜCHI acquires NIR-Online
Opto-electronic nose sniffs out toxic gases
ORNL scientists help explain graphene mystery
Altmann Analytik acquires lab supplier Dinkelberg analytics
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry - Cooperation between Bayer, the start-ups esqLABS and Dynamic42, and Placenta Lab of Jena University Hospital
New method provides more precise information on types of leukaemia - Optical genome mapping could become a component of routine diagnostics
Oxford Nanopore Announces Licence Agreement with Harvard University for Graphene DNA sequencing
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine - Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
World's first toxicology testing strategy without animal testing adopted by OECD - Success for long-standing collaboration between BASF and Givaudan to develop and validate alternative methods
Three Eyes See More than Two - monitoring a catalytic reaction with three different microscopies under exactly the same conditions in real time - Information is obtained that none of the methods alone could reveal
